SLAS Discovery

SLAS Discovery reports how scientists develop and use novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. The journal focuses on drug discovery sciences with a strong record of scientific rigor and impact, reporting on research that:

• Enables and improves target validation
• Evaluates current drug discovery technologies
• Provides novel research tools
• Incorporates research approaches that enhance depth of knowledge and drug discovery success

SLAS Discovery’s Editorial Scope includes: scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/ optimization; chemical biology; informatics (data analysis, image analysis, statistics, bio- and chemo-informatics); review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies

Publishes: annually in January, March, April, June, July, September, October and December

Advertising in Peer-Reviewed, Open Access Scientific Journals

The SLAS journals – SLAS Technology and SLAS Discovery – are now published Gold Open Access by Elsevier. Online advertising information is available from Kevin Partridge via email or call +44 (0)1865 843717.

Sponsorship opportunities